AGTR1 and chronic kidney disease: In support of this, it has been shown that the AT1 receptor antagonist, losartan, can prevent the development of CKD by maintaining renal blood flow, decreasing inflammation and tissue hypoxia following acute renal injury (Rodríguez-Romo et al., 2016).